日本神经精神药理学学会：《精神分裂症药物治疗指南》 - Suppr

Suppr

超能文献

Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

出版信息

Neuropsychopharmacol Rep. 2021 Sep;41(3):266-324. doi: 10.1002/npr2.12193. Epub 2021 Aug 12.

DOI:10.1002/npr2.12193

PMID:34390232

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8411321/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d8b/8411321/f0eb5cc1ea91/NPR2-41-266-g002.jpg

相似文献

Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Neuropsychopharmacol Rep. 2021 Sep;41(3):266-324. doi: 10.1002/npr2.12193. Epub 2021 Aug 12.

The 18th annual meeting of the Canadian College of Neuropsychopharmacology in Association with the Japanese Society of Neuropsychopharmacology. Vancouver, Canada, June 4-7, 1995.

J Psychiatry Neurosci. 1995 Nov;20(5):340-4.

[An introduction of the Translational Medical Science Committee (TMSC) of the Japanese Society of Neuropsychopharmacology].

Nihon Shinkei Seishin Yakurigaku Zasshi. 2014 Jun;34(3):81-6.

[Joint meeting of 28th annual meeting of the Japanese Society of Biological Psychiatry, 36th annual meeting of the Japanese Society of Neuropsychopharmacology, 49th annual meeting of the Japanese Society of Neurochemistry. Nagoya, Japan. September 14-26, 2006. Program and Abstracts].

Nihon Shinkei Seishin Yakurigaku Zasshi. 2006;Suppl:1-552.

Proceedings of the International Meeting on Japanese Psychopharmacology Algorithms. Yokohama, Japan, 23 April 1998. Proposals for the rational selections of drugs in the treatment of schizophrenia and mood disorders.

Psychiatry Clin Neurosci. 1999 Oct;53 Suppl:S1-82.

[The history of CINP between 1958 and 2000].

Nihon Shinkei Seishin Yakurigaku Zasshi. 2012 Aug;32(4):173-80.

[29th annual meeting of the Japanese Society of Neuropsychopharmacology. Hiroshima, Japan. September 14-15, 2000. Abstracts].

Nihon Shinkei Seishin Yakurigaku Zasshi. 1999 Dec;19(6):281-452.

[Proceeding of 26th annual meeting of the Japanese Society of Neuropsychopharmacology. Tokyo, Japan. October 24-25, 1996. Abstracts].

Nihon Shinkei Seishin Yakurigaku Zasshi. 1996 Dec;16(6):217-388.

[Proceeding of 33rd annual meeting of the Japanese Society of Neuropsychopharmacology. Nara, Japan. October 9-10, 2003. Abstracts].

Nihon Shinkei Seishin Yakurigaku Zasshi. 2003 Dec;23(6):223-359.

[Proceedings of 31st annual meeting of the Japanese Society of Neuropsychopharmacology. Hiroshima, Japan. October 4-5, 2001. Abstracts].

Nihon Shinkei Seishin Yakurigaku Zasshi. 2001 Dec;21(6):193-390.

引用本文的文献

Influence of pharmacokinetics-related gene polymorphisms on plasma levels of clozapine and its metabolites in Japanese patients with schizophrenia.

PCN Rep. 2025 Jul 30;4(3):e70164. doi: 10.1002/pcn5.70164. eCollection 2025 Sep.

High-Fat Meal Increase Blonanserin Bioavailability 5-Fold in Chinese Healthy Subjects.

Drug Des Devel Ther. 2025 Jul 15;19:6061-6072. doi: 10.2147/DDDT.S523344. eCollection 2025.

Association between pharmacological guideline adherence and actigraphy-measured sleep variables in long-term hospitalized patients with schizophrenia.

PCN Rep. 2025 Jul 10;4(3):e70154. doi: 10.1002/pcn5.70154. eCollection 2025 Sep.

Cognitive-behavioral therapy for the improvement of negative symptoms and functioning in schizophrenia: A systematic review and meta-analysis of randomized controlled trials.

PLoS One. 2025 May 20;20(5):e0324685. doi: 10.1371/journal.pone.0324685. eCollection 2025.

Associations between clozapine availability, the diagnosis of treatment-resistant schizophrenia subgroups, antipsychotic monotherapy, and concomitant psychotropics among patients with schizophrenia: a real-world nationwide study.

Int J Neuropsychopharmacol. 2025 Apr 11;28(4). doi: 10.1093/ijnp/pyaf011.

Proposal for a Novel Classification of Patients With Enlarged Ventricles and Cognitive Impairment Based on Data-Driven Analysis of Neuroimaging Results in Patients With Psychiatric Disorders.

Neuropsychopharmacol Rep. 2025 Mar;45(1):e70010. doi: 10.1002/npr2.70010.

Impact of psychotropic pro re nata prescription-monitoring programme on prescriptions for inpatients with psychiatric disorders: a retrospective observational study.

BMC Psychiatry. 2025 Jan 17;25(1):46. doi: 10.1186/s12888-025-06508-w.

Association between daytime sleepiness and quality of life in outpatients with schizophrenia.

Sleep Biol Rhythms. 2024 Oct 23;23(1):75-84. doi: 10.1007/s41105-024-00553-w. eCollection 2025 Jan.

Guideline for pharmacological treatment of schizophrenia 2022.

Neuropsychopharmacol Rep. 2025 Mar;45(1):e12497. doi: 10.1002/npr2.12497. Epub 2024 Nov 25.

The association between benzodiazepine prescriptions and the risk of laxative use in schizophrenia treatment.

Neuropsychopharmacol Rep. 2025 Mar;45(1):e12499. doi: 10.1002/npr2.12499. Epub 2024 Nov 7.

本文引用的文献

Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a cross-sectional and retrospective study.

J Clin Psychopharmacol. 2015 Feb;35(1):13-21. doi: 10.1097/JCP.0000000000000250.

Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study.

Am J Psychiatry. 2015 Jan;172(1):52-8. doi: 10.1176/appi.ajp.2014.13060787. Epub 2014 Oct 31.

Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.

Schizophr Res. 2014 Sep;158(1-3):213-22. doi: 10.1016/j.schres.2014.07.015. Epub 2014 Jul 31.

Retrospective study on the efficacy of a low-carbohydrate diet for impaired glucose tolerance.

Diabetes Metab Syndr Obes. 2014 Jun 13;7:195-201. doi: 10.2147/DMSO.S62681. eCollection 2014.

An open multicentre pilot study examining the safety, efficacy and tolerability of fast titrated (800 mg/day by day 4) quetiapine in the treatment of schizophrenia/schizoaffective disorder.

Int J Psychiatry Clin Pract. 2008;12(4):261-7. doi: 10.1080/13651500802085369.

Incidence and risk for neutropenia/agranulocytosis among clozapine users: A retrospective cohort study.

Int J Psychiatry Clin Pract. 2010 Jun;14(2):109-15. doi: 10.3109/13651500903402450. Epub 2009 Dec 29.

Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.

Schizophr Bull. 2015 Mar;41(2):449-59. doi: 10.1093/schbul/sbu067. Epub 2014 May 27.

Carbamazepine for schizophrenia.

Cochrane Database Syst Rev. 2014 May 2;2014(5):CD001258. doi: 10.1002/14651858.CD001258.pub3.

Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis.

Schizophr Bull. 2014 Nov;40(6):1385-403. doi: 10.1093/schbul/sbu030. Epub 2014 Mar 17.

Efﬁcacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.

Hum Psychopharmacol. 2012 Nov;27(6):605-14. doi: 10.1002/hup.2270.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验